01562nas a2200349 4500000000100000008004100001260001600042653001500058653001000073653001600083653001600099653001100115653002500126653001100151653001400162653001200176653002500188653003200213653001700245653002200262653001600284100001600300700002000316700001600336700001500352245004900367300001100416490000700427050001900434520074500453022001401198 2007 d c2007 Sep 28 10 aAdolescent 10 aAdult 10 aAge Factors 10 aBCG Vaccine 10 aBrazil 10 aCase-Control Studies 10 aHumans 10 aIncidence 10 aleprosy 10 aMycobacterium leprae 10 aSensitivity and Specificity 10 aTime Factors 10 aTreatment Outcome 10 aVaccination 1 aRodrigues L 1 aKerr-Pontes LRS 1 aFrietas MVC 1 aBarreto ML 00 aLong lasting BCG protection against leprosy. a6842-4 0 v25 aRODRIGUES 2007 3 aBACKGROUND: BCG vaccine protects against leprosy.
OBJECTIVES: Estimate BCG protection against leprosy by age by age.
METHODS: A case control study with 226 cases of leprosy and 857 controls. BCG vaccination was ascertained via examination of BCG scars. Protection is presented for three age groups.
RESULTS: BCG protection against leprosy was 86% (95% CI: 77-92%) in the age group 18-29; 54% (95% CI: -37% to 85%) in the age group 30-39 and 32% (95% CI: -3% to 56%) in those aged 40 or more.
CONCLUSIONS: BCG efficacy against leprosy may well last for three decades and possibly even longer. BCG vaccination must have contributed to worldwide reduction in leprosy incidence.
a0264-410X